Covid-fattened shares crash as FDA puts a late-stage coronavirus vaccine trial on hold
After seeing its market cap soar on the prospects of a highly-touted Covid-19 vaccine, Inovio saw its share price $INO led to slaughter on Monday after announcing that the FDA is forcing investigators to hit the brakes on a planned Phase II/III study.
The agency has some questions for Inovio right now, including queries related to “its Cellectra 2000 delivery device to be used in the trial.” But Inovio’s statement also didn’t spell out what the holdup was about, leaving considerable uncertainty about the fate of INO-4800:
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,000+ biopharma pros reading Endpoints daily — and it's free.